Back |
home / stock / nvo / nvo message board
Subject | By | Source | When |
---|---|---|---|
***NOW COMPARE $NVO M WITH$ SPX M | TREND1 | investorshub | 10/24/2014 1:04:54 AM |
No action yet. | DewDiligence | investorshub | 10/23/2014 8:53:03 PM |
$NVO M | TREND1 | investorshub | 10/23/2014 8:39:58 PM |
$NVO is world's biggest maker of insulin | TREND1 | investorshub | 10/23/2014 8:08:43 PM |
$NVO D | TREND1 | investorshub | 10/23/2014 8:06:45 PM |
$NVO 1 | TREND1 | investorshub | 10/23/2014 8:01:33 PM |
DEW How did this turn out ? | TREND1 | investorshub | 10/23/2014 7:39:33 PM |
Novo is studying the injected drug - already | TREND1 | investorshub | 10/23/2014 7:31:29 PM |
Share buyback started Feb 1st. Also | a surfer | investorshub | 03/01/2014 8:32:56 PM |
Final push before reversal IMO. | Ichauway | investorshub | 03/01/2014 8:13:13 PM |
Agreed but I do see this eventually higher. | a surfer | investorshub | 02/25/2014 5:58:49 PM |
Looks like a good day to take some profits. | Ichauway | investorshub | 02/25/2014 5:52:36 PM |
This thing is a monster!! Share buy | a surfer | investorshub | 02/25/2014 5:49:57 PM |
diabetes market to be $58 billion by 2018 | Ichauway | investorshub | 01/01/2014 3:12:05 AM |
A recent article on insidermonkey makes an interesting | investora2z | investorshub | 08/08/2013 10:35:24 AM |
Great company, but the valuation is a little | DewDiligence | investorshub | 07/18/2013 4:31:19 PM |
Novo is a good growth story as far | investora2z | investorshub | 07/18/2013 11:19:49 AM |
Novo bets on high-price niche for obesity drug | Wildbilly | investorshub | 12/11/2012 11:03:19 PM |
FDA extends NDA review of NVOs degludec and | DewDiligence | investorshub | 06/08/2012 12:25:14 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...